MARGERY A. CONNELLY, PHD, MBA
VICE PRESIDENT, TRANSLATIONAL RESEARCH
RESEARCH AND DEVELOPMENT
LABCORP (LIPOSCIENCE )
RALEIGH, N.C.
CONNEM 5@ LABCORP . COM
PREVIOUS
JANSSEN, PHARMACEUTICAL COMPANIES OF JOHNSON AND JOHNSON,
STONY BROOK UNIVERSITY SCHOOL OF MEDICINE , DEPARTMENT OF PHARMACOLOGICAL SCIENCES
EDUCATION
PHD- STONY BROOK UNIVERSITY SCHOOL OF MEDICINE , DEPARTMENT OF P ATHOLOGY AND IMMUNOLOGY
MBA- DREXEL UNIVERSITY – LEBOW COLLEGE OF BUSINESS
RESEARCH INTERESTS INCLUDE :
CARDIOVASCULAR DISEASE, DIABETES, OBESITY, INFLAMMATION, THERAPEUTICS, DIAGNOSTICS AND PERSONALIZED MEDICINE
KEY AREAS OF ACCOMPLISHMENTS AND EXPERTISE:
DR. CONNELLY IS A FELLOW OF THE AMERICAN HEART ASSOCIATION. WHILE ON THE FACULTY OF STONY BROOK UNIVERSITY, HER
RESEARCH FOCUS WAS LIPOPROTEIN METABOLISM , INFLAMMATION AND ATHEROSCLEROSIS . I N 2004, SHE ACCEPTED A POSITION AT
JANSSEN R&D WHERE SHE APPLIED HER EXPERTISE IN PHARMACOLOGY , ATHEROSCLEROSIS , METABOLIC DISEASE AND LIPID
METABOLISM TO DRUG DISCOVERY RESEARCH . WHILE AT JANSSEN, SHE WAS PROMOTED TO PRINCIPAL SCIENTIST , ATHEROSCLEROSIS
GROUP LEADER AND EVENTUALLY LED THE CELLULAR AND BIOCHEMICAL PHARMACOLOGY SECTION OF THE CARDIOVASCULAR AND
METABOLIC DISCOVERY RESEARCH TEAM . SHE PLAYED A KEY ROLE IN BUILDING COLLABORATIVE RELATIONSHIPS WITH ACADEMIC
LABS AND BIOTECH COMPANIES IN ORDER TO EXPAND JANSSEN’ S RESEARCH CAPABILITIES. BEFORE LEAVING JANSSEN , SHE WAS
PROMOTED TO SCIENTIFIC DIRECTOR AND RECEIVED THE TITLE OF JANSSEN FELLOW IN RECOGNITION OF HER GLOBAL SCIENTIFIC
ACCOMPLISHMENTS. I N 2013, SHE JOINED LIPO SCIENCE , A DIAGNOSTIC COMPANY IN NC, WHICH IS NOW PART OF LABC ORP. IN
HER CURRENT ROLE AS VP OF T RANSLATIONAL RESEARCH, SHE HAS BEEN APPLYING HER SCIENTIFIC EXPERTISE AND LEADERSHIP
EXPERIENCE TOWARD THE DEVELOPMENT OF NEW NMR-BASED IN VITRO DIAGNOSTICS FOR THE DIAGNOSIS AND PROGNOSIS OF
VARIOUS DISEASES INCLUDING CARDIOVASCULAR , METABOLIC SYNDROME , DIABETES, OBESITY , INFLAMMATION , LIVER DISEASE ,
RHEUMATOLOGY AND ONCOLOGY .